

**King, Valerie A.**

---

**From:** King, Valerie A.  
**Sent:** Wednesday, February 26, 2003 6:08 PM  
**To:** Carchman, Loreen  
**Cc:** Venable-Waple, Bristow (RD &E)  
**Subject:** RE: Project Agreements for Repeat Menthol Study

Loreen:

I learned today that the sample analysis for this study will be performed entirely in-house at MDS. We will not, therefore, need a sample analysis agreement with Covance.

I am still trying to get the fee proposal from MDS for the clinical work; the protocol revision was only received by PM on Monday and Kim is in Japan. I have asked for someone to work on it in her absence, but am not clear on whether I will get it this week.

We will still need a PA for monitoring. I will forward a fee once I receive it.

Thanks,  
Valerie

-----Original Message-----

**From:** King, Valerie A.  
**Sent:** Thursday, February 13, 2003 11:09 AM  
**To:** Carchman, Loreen  
**Cc:** Venable-Waple, Bristow (RD &E)  
**Subject:** Project Agreements for Repeat Menthol Study

Loreen:

Just a head's up to let you know that I should have a proposed fee for the clinical piece of the repeat menthol study for your review and incorporation into a project agreement next week. I had hoped to provide it to you this week, but the study design is still being finalized. As it currently stands, we are targeting an IRB submission for the protocol and ICF on March 5 (for IRB review on March 11). Clinical confinement is scheduled to begin on April 24. Screening will take place in early April.

Based on the above, I am attaching the proposed timing for completion of the three project agreements that will need to be in place for this agreement.

Please let me know if you have any questions. Otherwise, I will forward you the fee proposals as soon as possible.

Thanks,  
Valerie

<< File: JLI Menthol PA Schedule.xls >>